Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 2/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834603 | 0.86 | BAZ1A (0.41) | KCNQ2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4828973 | 0.86 | BAZ1A (0.41) | KCNQ2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4835290 | 0.80 | RAB9A (0.49) | SMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL4836546 | 0.79 | KDM4E (0.52) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4833753 | 0.74 | SCN3A (0.51) | SMN1; SMN2ALDH1A1LMNAHTTHDAC3 | |
| SCHEMBL4833891 | 0.74 | MAPT (0.54) | SMN1; SMN2ALDH1A1LMNATP53 | |
| SCHEMBL4831085 | 0.74 | SCN3A (0.51) | SMN1; SMN2ALDH1A1LMNAHTTHDAC3 | |
| SCHEMBL4833596 | 0.73 | MAPK8 (0.45) | SMN1; SMN2LMNA | |
| SCHEMBL4833486 | 0.71 | MAPT (0.50) | SMN1; SMN2ALDH1A1LMNAHTTHDAC1 | |
| SCHEMBL4833496 | 0.71 | MAPT (0.50) | SMN1; SMN2ALDH1A1LMNAHTTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | claimed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | claimed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | claimed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | KCNQ2 2778/4885SMN1; SMN2 4268/4885ALDH1A1 906/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | KCNQ2 2050/4885SMN1; SMN2 3836/4885ALDH1A1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.